- Home
- HRMY vs SHCO Comparison
HRMY vs SHCO Comparison
Compare HRMY & SHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- SHCO
- Stock Information
- Founded
- HRMY 2017
- SHCO 1995
- Country
- HRMY United States
- SHCO United Kingdom
- Employees
- HRMY N/A
- SHCO N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- SHCO Hotels/Resorts
- Sector
- HRMY Health Care
- SHCO Consumer Discretionary
- Exchange
- HRMY Nasdaq
- SHCO Nasdaq
- Market Cap
- HRMY 1.9B
- SHCO 1.7B
- IPO Year
- HRMY 2020
- SHCO 2021
- Fundamental
- Price
- HRMY $26.11
- SHCO $8.86
- Analyst Decision
- HRMY Strong Buy
- SHCO Strong Buy
- Analyst Count
- HRMY 10
- SHCO 1
- Target Price
- HRMY $50.80
- SHCO $9.00
- AVG Volume (30 Days)
- HRMY 1.0M
- SHCO 450.7K
- Earning Date
- HRMY 10-28-2025
- SHCO 08-08-2025
- Dividend Yield
- HRMY N/A
- SHCO N/A
- EPS Growth
- HRMY 58.41
- SHCO N/A
- EPS
- HRMY 3.10
- SHCO N/A
- Revenue
- HRMY $772,527,000.00
- SHCO $1,251,591,000.00
- Revenue This Year
- HRMY $19.94
- SHCO $11.89
- Revenue Next Year
- HRMY $16.65
- SHCO $7.87
- P/E Ratio
- HRMY $8.37
- SHCO N/A
- Revenue Growth
- HRMY 17.74
- SHCO 9.00
- 52 Week Low
- HRMY $25.58
- SHCO $4.60
- 52 Week High
- HRMY $41.61
- SHCO $8.92
- Technical
- Relative Strength Index (RSI)
- HRMY 30.89
- SHCO 63.82
- Support Level
- HRMY $25.95
- SHCO $8.81
- Resistance Level
- HRMY $26.97
- SHCO $8.87
- Average True Range (ATR)
- HRMY 0.79
- SHCO 0.02
- MACD
- HRMY 0.19
- SHCO -0.03
- Stochastic Oscillator
- HRMY 26.11
- SHCO 40.00
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SHCO Soho House & Co Inc.
Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create, and flourish all over the world. It offers lease agreements for Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are: United Kingdom; The Americas; and Europe and Rest of the world. The majority of its revenue is generated from the Americas segment, which encompasses its operating units in the Americas, including Soho Houses, stand-alone U.S. restaurants, Soho Friends, and the management fees under a hotel management contract for the operation of The Ned London.